Recent advances in non-small cell lung cancer targeted therapy; an update review
Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last
decade, significant advancements in the diagnosis and treatment of lung cancer, particularly …
decade, significant advancements in the diagnosis and treatment of lung cancer, particularly …
Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs
W Jiang, J Xia, S Xie, R Zou, S Pan, Z Wang… - Drug Resistance …, 2020 - Elsevier
Chemoresistance including intrinsic and acquired anticancer drug resistance continues to
be a primary hindrance towards curative cancer treatment. Therefore, deciphering the …
be a primary hindrance towards curative cancer treatment. Therefore, deciphering the …
[HTML][HTML] Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or …
Y Chen, S Wen, Y Wu, L Shi, X Xu, B Shen - Critical Reviews in Oncology …, 2021 - Elsevier
Objective We conducted a meta-analysis to synthesize the results of published randomized
controlled trials conducted to evaluate the efficacy and safety of epidermal growth factor …
controlled trials conducted to evaluate the efficacy and safety of epidermal growth factor …
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation
T Landre, G Des Guetz, K Chouahnia… - Journal of Cancer …, 2020 - Springer
Purpose Erlotinib is indicated as first-line treatment for patients with non-small-cell lung
cancer (NSCLC) harboring an epidermal growth-factor–receptor (EGFR) mutation. Addition …
cancer (NSCLC) harboring an epidermal growth-factor–receptor (EGFR) mutation. Addition …
Targeting tumor endothelial cells with methyltransferase inhibitors: mechanisms of action and the potential of combination therapy
S Zhou, H Ou, Y Wu, D Qi, X Pei, X Yu, X Hu… - Pharmacology & …, 2023 - Elsevier
Tumor endothelial cells (TECs) reside in the inner lining of blood vessels and represent a
promising target for targeted cancer therapy. DNA methylation is a chemical process that …
promising target for targeted cancer therapy. DNA methylation is a chemical process that …
Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations
KB Winfree, C Molife, PM Peterson, Y Chen… - Future …, 2021 - Taylor & Francis
Aim: To estimate real-world (rw) outcomes for first-line therapy in patients with advanced
EGF receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), focusing on specific …
EGF receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), focusing on specific …
[HTML][HTML] The differential prognostic implications of PD-L1 expression in the outcomes of Filipinos with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
HGC Luna, MS Imasa, N Juat… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
Background The tumor immune microenvironment influences tumor evolution in non-small
cell lung cancer (NSCLC). Yet, the prognostic value of programmed death-ligand 1 (PD-L1) …
cell lung cancer (NSCLC). Yet, the prognostic value of programmed death-ligand 1 (PD-L1) …
Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials
B Mangla, P Mittal, P Kumar, G Aggarwal - Medical Oncology, 2024 - Springer
Erlotinib (ELB) is a tyrosine kinase inhibitor that targets the activity of Epidermal Growth
Factor Receptor (EGFR) protein found in both healthy and cancerous cells. It binds …
Factor Receptor (EGFR) protein found in both healthy and cancerous cells. It binds …
Optimization of process parameters for bevacizumab-loaded nanodispersion for lung cancer treatment
V Sethuraman, A Ramesh, K Janakiraman… - Journal of Dispersion …, 2024 - Taylor & Francis
Lung cancer is one of the most common and lethal types of cancer worldwide, needing
novel therapeutic approaches to enhance patient outcomes. Nanotechnology has emerged …
novel therapeutic approaches to enhance patient outcomes. Nanotechnology has emerged …
[HTML][HTML] 晚期非小细胞肺癌抗血管生成药物的联合治疗模式
许子宜， 李峻岭 - Chinese Journal of Lung Cancer, 2021 - ncbi.nlm.nih.gov
晚期非小细胞肺癌的治疗方案包括化疗、 针对驱动基因的靶向治疗以及以免疫检查点抑制剂为
代表的免疫治疗， 疗效仍待进一步提高， 而联合治疗是当前研究热点。 抗血管生成药物在晚期 …
代表的免疫治疗， 疗效仍待进一步提高， 而联合治疗是当前研究热点。 抗血管生成药物在晚期 …